Published: 2016-02-16

Homocysteine – relation to hypertension, age and smoking in patients with newly diagnosed essential hypertension

Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
homocysteine hypertension blood pressure


Introduction. An elevated circulating concentration of homocysteine is associated with an increased risk of coronary, cerebral, and peripheral vascular disease. The purpose of this study was to determine the concentrations of homocysteine in the patients with newly diagnosed essential hypertension and healthy subjects and to analyze the correlation between homocysteine level and the other parameters (age, blood pressure, smoking).
Material and methods. The study group consisted of 18 patients with essential hypertension, 4 women and 14 men (mean age 43 ± 16 years) and 15 healthy volunteers, 8 women and 7 men (mean age 47 ± 10 years). Serum homocysteine was analyzed by FPIA method (Fluorescence Polarization Immunoassay).
Results. The patients with essential hypertension had significantly higher homocysteine concentration compared to control group. No correlation was observed between homocysteine levels and age, diastolic, systolic blood pressure in subjects with essential hypertension. In healthy volunteers, only a correlation between age and homocysteine concentration was found.


Download data is not yet available.


  1. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015 Jan 10;14:6. doi: 10.1186/1475–2891–14–6.
  2. Atif A, Rizvi MA, Tauheed S, Aamir I, Majeed F, Siddiqui K, Khan S. Serum homocysteine concentrations in patients with hypertension. Pak J Physiol. 2008;4(1): 21–22.
  3. Marinou K, Antoniades C, Tousoulis D, Pitsavos C, Goumas G, Stefanadis C. Homocysteine: a risk factor for coronary artery disease? Hellenic J Cardiol. 2005;46(1):59–67.
  4. Faeh D, Chiolero A, Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about it? Swiss Med Wkly. 2006;136:745–756.
  5. Leal AA, Palmeira AC, Castro GM, Simoes MO, Ramos AT, Medeiros CC. Homocysteine: cardiovascular risk factor in children and adolescents? Rev Assoc Med Bras. 2013;59(6):622–628.
  6. Giannoni M, Consales V, Campanati A, Ganzetti G, Giuliodori K, Postacchini V et al. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. J Eur Acad Dermatol Venereol. 2015 Mar 23. doi: 10.1111/jdv.13023. [Epub ahead of print]
  7. Baszczuk A, Kopczynski Z, Thielemann A. Endothelial dysfunction in patients with primary hypertension and hyperhomocysteinemia. Postepy Hig Med Dosw 2014; 68:91–100.
  8. Lim U, Cassano PA. Homocysteine and Blood Pressure in the Third National Health and Nutrition Examination Survey, 1988–1994. Am J. Epidemiol. 2002;156(12): 1105–1113.
  9. Sen U, Tyagi SC. Homocysteine and Hypertension in Diabetes: Does PPAR? Have a Regulatory Role? PPAR Res. 2010; 2010: 806538.
  10. Vermeulen EG, Niessen HW, Bogels M, Stehouwer CD, Rauwerda JA., van Hinsbergh VW. Decreased smooth muscle cell/extracellular matrix ratio of media of femoral artery in patients with atherosclerosis and hyperhomocysteinemia. Arterioscler Thromb Vas Biol 2001;21(4):573–577.
  11. Stehouwer CD, van Guldener C. Does homocysteine cause hypertension? Clin Chem Lab Med. 2003;41(11): 1408–1411.
  12. van Guldener CP, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Current Hypertension Reports. 2003;5(1):26–31.
  13. Nakhai-Pour HR, Grobbee DE, Bots ML, Muller M, van der Schouw YT. Circulating homocysteine and large arterial stiffness and thickness in a population-based sample of middle-aged and elderly men. J Hum Hypertens. 2007;21:942–948.
  14. Ruan L, Chen W, Srinivasan SR, Xu J, Sun M, Toprak A, Berenson GS. Relation of plasma homocysteine to arterial stiffness in black and white young adults (from the Bogalusa Heart Study) Am J Cardiol. 2009;103:985–988.
  15. Levy D, Hwang SJ, Kayalar A, Benjamin EJ, Vasan RS, Parise H et al. Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: the Framingham Heart Study. Circulation. 2007;115:3079–3085.
  16. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–1057.
  17. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775–1781.
  18. Animesh K, Mehrotra V. Trends in blood pressure with increasing plasma homocysteine levels. JIACM 2014; 15(3–4):188–191.
  19. Sheu WH, Lee WJ, Chen YT. Plasma homocysteine concentration and insulin sensitivity in hypertensive subjects. Am J Hypertens. 2000;13(1 Pt 1):14–20.
  20. Kahleova R, Palyzova D, Zvara K, Zvarova J, Hrach K, Novakova I, et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002;15(10 Pt 1):857–864.
  21. Ustundag S, Arikan E, Sen S, Esgin H, Ciftci S. The relationship between the levels of plasma total homocysteine and insulin resistance in uncomplicated mild-to-moderate primary hypertension. J Hum Hypertens, 2006;20(5):379–81.
  22. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation. 1997;96:1745–1749.
  23. Głowinska B, Urban M, Koput A, Galar M. New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. Atherosclerosis. 2003;167:275–286.
  24. Dinavahi R, Cossrow N, Kushner H, Falkner B. Plasma homocysteine concentration and blood pressure in young adult African Americans. Am J Hypertens. 2003;16:767–770.
  25. Sundström J, Sullivan L, D’Agostino RB. Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking.The Framingham Heart Study. Hypertension. 2003;42:1100.
  26. Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003;41:1444–1454.
  27. Rodriguez-Esparragon F, Caballero-Hidalgo A, Hernandez-Trujillo Y, Macias-Reyes A, Rodriguez-Perez JC. Concerning Arterial Hypertension, Homocysteine and Paraoxonase-1. Current Hypertension Reviews. 2007;3:51–57.
  28. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248–252.
  29. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and EssentialHypertension. J Clin Pharmacol December 2003: 43 (12):1299–1306.
  30. Steed MM, Tyagi SC. Mechanisms of Cardiovascular Remodeling in Hyperhomocysteinemia Antioxid Redox Signal.2011;15(7):1927–1943.
  31. O’Callaghan P, Meleady R, Fitzgerald T, Graham I. Smoking and plasma homocysteine. European Heart Journal 2002; 23: 1580–1586.
  32. Yildirim A, Keleş F, Özdemir G, Koşger P, Uçar B, Alataş Ö, Kiliç Z. Homocysteine levels in normotensive children of hypertensive parents. Anatol J Cardiol. 2015 Apr 2. doi: 10.5152/akd.2015.5862. [Epub ahead of print]
  33. Catena C, Colussi G, Url-Michitsch M, Nait F, Sechi LA. Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension. J Am Soc Hypertens. 2015 Mar;9(3):167–75.

How to Cite

Korzeniowska K, Cieślewicz A, Chmara E, Jabłecka A. Homocysteine – relation to hypertension, age and smoking in patients with newly diagnosed essential hypertension. JMS [Internet]. 2016Feb.16 [cited 2020Aug.5];84(2):90-6. Available from: